GlassScriptPhysician profile
Mark Allen Ng Ramirez
NPI 1245400209
$14,182.33
in general payments reported to CMS, 2019-2025
55 companies · $2,624 in 2025
The $2,624 reported for 2025 was more than what 77% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,609 · 2020: $1,413 · 2021: $1,690 · 2022: $2,029 · 2023: $2,223 · 2024: $2,594 · 2025: $2,624.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,271 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,271.14 |
| Education | $169.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,308.72 | 2021-2025 | |
| Lundbeck LLC | $1,013.48 | 2019-2025 | Vyepti |
| Neurocrine Biosciences, INC. | $948.82 | 2019-2025 | Ingrezza, Ongentys |
| Teva Pharmaceuticals USA, INC. | $860.36 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Sunovion Pharmaceuticals INC. | $753.73 | 2019-2022 | |
| Ucb, INC. | $726.07 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Novartis Pharmaceuticals Corporation | $557.83 | 2019-2025 | |
| Pfizer INC. | $556.17 | 2019-2025 | |
| Amgen INC. | $469.88 | 2019-2023 | Aimovig |
| Upsher-Smith Laboratories LLC | $459.53 | 2019-2023 | |
| Allergan, INC. | $366.67 | 2019-2021 | |
| Sk Life Science, INC. | $323.73 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $307.09 | 2020-2022 | |
| Genentech USA, INC. | $306.91 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Biogen, INC. | $303.90 | 2019-2022 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Allen Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.